Biocryst Pharmaceuticals (BCRX) Non Operating Income (2024 - 2026)

Biocryst Pharmaceuticals has reported Non Operating Income for 3 years, with the latest figure at -$19.2 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income rose 6.15% year-over-year to -$19.2 million; the trailing twelve-month figure through Mar 2026 stood at -$72.3 million (up 14.24% YoY), and the FY2025 full-year result was -$73.6 million, up 12.81% from the prior year.
• Non Operating Income for Q1 2026 stood at -$19.2 million, down from -$12.4 million in the prior quarter.
• The five-year high for Non Operating Income was -$12.4 million in Q4 2025, with the low at -$23.3 million in Q2 2025.
• Historically, Non Operating Income has averaged -$19.7 million across 3 years, with a median of -$20.5 million in 2024.
• The largest YoY upside for Non Operating Income was 42.43% in 2025 against a maximum downside of 9.58% in 2025.
• Biocryst Pharmaceuticals' Non Operating Income stood at -$21.5 million in 2024, then soared by 42.43% to -$12.4 million in 2025, then tumbled by 55.32% to -$19.2 million in 2026.
• The last three Non Operating Income figures came in at -$19.2 million (Q1 2026), -$12.4 million (Q4 2025), and -$17.5 million (Q3 2025), per Business Quant data.